TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from Medical Developments International Limited ( (AU:MVP) ).
Medical Developments International Limited announced the appointment of Mr. Mark Fladrich as the new Chair of the Board, effective December 1, 2025, succeeding Mr. Gordon Naylor. Mr. Fladrich, with over 30 years of experience in the pharmaceutical industry, is expected to bring significant commercial and strategic expertise to the company, particularly in pain management. This leadership transition is anticipated to strengthen MVP’s market position and support the company’s strategic objectives, including the growth of Penthrox. Additionally, the Board has created a Deputy Chair role, appointing Mr. Paul Townsend, to further enhance governance.
The most recent analyst rating on (AU:MVP) stock is a Buy with a A$0.80 price target. To see the full list of analyst forecasts on Medical Developments International Limited stock, see the AU:MVP Stock Forecast page.
More about Medical Developments International Limited
Medical Developments International Ltd (MVP) is an Australian company specializing in emergency medical solutions aimed at improving patient outcomes. MVP is recognized as a leader in emergency pain relief and respiratory products, notably manufacturing Penthrox®, a fast-acting, non-opioid pain relief product used in various medical settings including hospitals, ambulance services, and defense forces.
Average Trading Volume: 157,016
Technical Sentiment Signal: Buy
Current Market Cap: A$78.86M
For a thorough assessment of MVP stock, go to TipRanks’ Stock Analysis page.